<DOC>
	<DOCNO>NCT01351675</DOCNO>
	<brief_summary>This study assess efficacy bardoxolone methyl relative placebo delay progression end-stage renal disease ( ESRD ) cardiovascular death patient Stage 4 Chronic Kidney Disease ( CKD ) type 2 diabetes receive standard care .</brief_summary>
	<brief_title>Bardoxolone Methyl Evaluation Patients With Chronic Kidney Disease Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>1 . Screening eGFR ≥ 15.0 &lt; 30.0 mL/min/1.73 m2 ; 2 . A history type 2 diabetes ; diagnosis make ≥ 30 year age ; 3 . Male female least 18 year age ; 4 . Treatment angiotensin convert enzyme ( ACE ) inhibitor and/or angiotensin II receptor blocker ( ARB ) least 6 week prior screen . Stable dose 2 week prior screen . Patients take ACE inhibitor and/or ARB medical contraindication must discontinue treatment least 8 week prior Screening Visit A ; 5 . Mean systolic blood pressure ( SBP ) must ≤ 160 mmHg ≥ 105 mmHg mean diastolic blood pressure ( DBP ) must &lt; 90 mm Hg screening ; mean SBP mean DBP ( determine average three reading ) must within range two separate time point measure least 4 day apart screen period ( blood pressure may reevaluate unscheduled visit ) ; 6 . Willing practice method birth control ( male female patient ) entire study period least 30 day last dose study drug ingest ; 7 . Serum magnesium level must ≥ 1.3 mEq/L ( 0.65 mmol/L ) Screening Visit B subsequent unscheduled visit screening ( serum magnesium level may reevaluate unscheduled visit ) ; 8 . Willing able cooperate aspect protocol ; 9 . Willing able give write informed consent study participation provide consent access medical data accord appropriate local data protection legislation , allow authorization access medical record describe event capture endpoint 1 . Type 1 diabetes mellitus ( juvenile onset ) . If history diabetic ketoacidosis exists , Cpeptide level must confirm type 2 diabetes ; 2 . Known nondiabetic renal disease ( e.g. , polycystic kidney disease , focal segmental glomerulosclerosis ) [ nephrosclerosis superimpose diabetic kidney disease acceptable ] ; 3 . Ongoing clinical evidence suggest nondiabetic renal disease nephrosclerosis ; 4 . History renal transplant plan transplant live donor study ; 5 . Albumin creatinine ratio ( ACR ) great 3500 mg/g ( 395.5 mg/mmol ) ; 6 . Hemoglobin A1c level &gt; 11.0 % ( 97 mmol/mol ) screening ; 7 . Acute dialysis acute kidney injury within 12 week prior screen screen ; 8 . Clinical sign and/or symptom uremia expect need renal replacement therapy within 12 week follow randomization , assessed investigator ; 9 . Recently active cardiovascular disease define : a. Unstable angina pectoris within 12 week study randomization ; b. Myocardial infarction , coronary artery bypass graft surgery , percutaneous transluminal coronary angioplasty/stent within 12 week study randomization ; c. Cerebrovascular accident , include transient ischemic attack within 12 week study randomization ; d. Current diagnosis Class III IV New York Heart Association ( NYHA ) congestive heart failure ; 10 . Clinical diagnosis severe obstructive valvular heart disease severe obstructive hypertrophic cardiomyopathy ; 11 . Atrioventricular block , 2o 3o , successfully treat pacemaker ; 12 . DAdministration contrast agent may induce nephropathy within 30 day prior study randomization plan study ; 13 . Systemic immunosuppression total &gt; 2 week , cumulatively , within 12 week prior randomization plan study ; 14 . Total bilirubin , aspartate aminotransaminase ( AST ) alanine aminotransaminase ( ALT ) level great upper limit normal ( ULN ) , alkaline phosphatase level great two time ULN ANY screen laboratory test result ; 15 . Female patient pregnant , intend become pregnant study , nursing ; 16 . BMI &lt; 18.5 g/m2 17 . Known hypersensitivity component study drug ; 18 . Current history drug alcohol abuse assess investigator ; 19 . Clinically significant infection require intravenous administration antibiotic hospitalization within 6 week screen screening ; 20 . Hepatitis B surface antigen positive ; 21 . Diagnosis treatment malignancy past 5 year , exclude nonmelanoma skin cancer carcinoma situ cervix condition highly likely transform malignancy course study ; 22 . A clinical condition judgment investigator could potentially pose health risk patient involve study ; 23 . Participation clinical study involve intervention within 30 day prior randomization , concurrent participation study , participation prior clinical study involve bardoxolone methyl form ; 24 . Unable communicate cooperate investigator due language problem , poor mental development impair cerebral function .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Chronic kidney disease</keyword>
	<keyword>Type 2 diabetes</keyword>
	<keyword>Diabetic nephropathy</keyword>
</DOC>